by Entheogen Biomedical | Dec 4, 2020 | Company News
Originally published at https://www.newsfilecorp.com/release/69518 Vancouver, BC – December 4, 2020 – Entheon Biomedical Corp. (CSE: “ENBI”) (FSE:1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat...
by Entheogen Biomedical | Dec 1, 2020 | Company News
Centre for Human Drug Research led DMT study to start in 2021 Vancouver, BC – December 1, 2020 – Entheon Biomedical Corp. (“Entheon” or the “Company”) (CSE: ENBI) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat...
by Entheogen Biomedical | Nov 6, 2020 | Company News
Original Source – Newsfile Corp. Vancouver, British Columbia–(Newsfile Corp. – November 5, 2020) – Entheon Biomedical Corp. (CSE: MPV) (formerly, MPV Exploration Inc.) (“Entheon” or the “Company”) is pleased to announce...
by Entheogen Biomedical | Oct 28, 2020 | Company News
MONTRÉAL, 28 oct. 2020 (GLOBE NEWSWIRE) — Exploration MPV Inc. (« MPV » ou la « Société ») est heureuse d’annoncer que suite à ses communiqués de presse datées du 2 juillet 2020 et du 10 septembre 2020 (les « communiqués de presse initiaux »...
by Entheogen Biomedical | Oct 28, 2020 | Company News
MONTREAL, Oct. 28, 2020 (GLOBE NEWSWIRE) — MPV Exploration Inc. (“MPV” or the “Company”) is pleased to announce that further to its news releases dated July 2, 2020 and September 10, 2020 (the “Initial News Releases”), the Company has...
by Entheogen Biomedical | Sep 21, 2020 | Company News
Dr. Andrew Hegle currently serves as Entheon Biomedical’s Director of Operations. He has been an adjunct professor of Pharmacology at the University of British Columbia since 2015. He has a background in molecular biology and biochemistry and has published...
Recent Comments